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A commentary on
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Inflammation is a constant feature of tumors. The tumor microenvironment (TME) is rich in
inflammatory cells and inflammatory mediators that strongly affect tumor growth and progression
as well as metastatic spreading. It has been known for a while that tumor-infiltrating inflammatory
cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAM)
promote tumor growth, and accordingly several soluble factors, such as the CCL2 chemokine, the
pro-inflammatory cytokines IL-1, IL-6, and TNFα, the pro-angiogenic factor VEGF are enriched in
the TME (1). Nevertheless, no oncogene or oncosuppressor genes have been so far found to encode
molecules belonging to the humoral innate immune system.
A main constituent of the soluble arm of innate immunity are the pentraxins, a superfamily of
highly conserved immune effector molecules comprised the short pentraxins (C reactive protein,
CRP, and serum amyloid P, SAP, component) and the long pentraxin PTX3 (2). Pentraxins
interact with complement and with complement-regulating factors to effect microbe recognition
and disposal, with wide-range implications for host defense and regulation of inflammation. Short
pentraxins are synthesized in the liver and released in the blood at the inception of inflammation.
On the contrary, PTX3 is produced locally, not only by macrophages and neutrophils but also
by endothelial and smooth muscle cells, in response to cytokines, pathogen-associated molecular
patterns (PAMPs), intact microbes, oxidized-LDL, or HDL. PTX3 has been shown to play an
important role in resistance against selected pathogens, and is under evaluation as an antimicrobic
agent.
Bonavita et al. now show that PTX3 has a pivotal role in controlling tumor growth, and this is
related to its ability to modulate the inflammatory response (3). Carcinogenesis was investigated
in Ptx3 /  and Ptx3+/+ mice treated with 3-methylcholantrene (3-MCA) or 7,12-dimethylbenz
[α] anthracene/terephthalic acid (DMBA/TPA) to induce formation of sarcomas or papillomas/skin
carcinomas, respectively. Twice as many Ptx3 /  mice developed sarcomas compared to Ptx3+/+,
and incidence and multiplicity of papillomas and progression to carcinomas were also much higher
in Ptx3 /  than in Ptx3+/+. Interestingly, and in support of the prevalent origin of PTX3 from
immune cells, the main source of PTX3 were infiltrating leukocytes and endothelial cells, but not
tumor cells. Since PTX3 had no direct effects on tumor cell growth, attention was focused on
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cancer-related inflammation (CRI). Sarcomas growing in
Ptx3 /  host showed a much higher macrophage and neutrophil
infiltrate, and higher levels of CCL2, CXCL2, TNFα, IL-6, IL-1β,
and VEGF, suggesting an exacerbated tumor-associated inflam-
matory response. The crucial mechanistic link to dysregulated
activation of inflammation in the Ptx3 /  mice was shown
to be complement activation. Both C3 and C5a were found to
be deposited in higher amounts in Ptx3 /  versus Ptx3+/+
homogenates, while the complement regulatory protein factor
H was found significantly lower, suggesting that lack of PTX3
caused an unrestricted activation of complement-dependent
inflammation as a consequence of defective factor H recruitment.
Inflammation is likely promoting cancer viamultiple pathways,
such as inhibition of anti-tumor cytotoxic responses, secretion of
growth-promoting cytokines, release of angiogenic factors, but it
may also favor tumor genetic instability. Bonavita et al. addressed
this issue by investigating frequency of mutations in two genes,
Trp53 and Kras, that are target of several carcinogens, 3-MCA
included (3). Quite interestingly, while frequency of Kras muta-
tions was not increased, frequency of Trp53mutations was signif-
icantly higher in Ptx3 /  versus Ptx3+/+mice, pointing to a pro-
gressive loss of Trp53-dependent oncosuppressor function in the
Ptx3 /  host. Of relevance for human pathology, the Ptx3 gene
was found to be silenced bymethylation in several human tumors.
Macrophages, MDSCs, several cytokines, and growth factors
are thought to be essential components of the TME and have a
prominent role in tumor progression (4), while complement was
not included so far within the components of tumor-promoting
inflammation. Now, the study by Bonavita et al. shows that
complement should be considered a factor of cancer-promoting
inflammation in its own right, and identifies the long pentraxin
PTX3 as a crucial modulator of the complement-dependent
tumor-promoting pathway (3). These observations, on one hand,
underline the role of PTX3 as an extrinsic tumor suppressor gene,
and on the other, give an additional, paradigmatic, demonstration
of the fundamental role played by inflammation in tumorigenesis.
Chronic, low-grade inflammation is a constant feature of all
malignant tumors, whether they are epidemiologically related to
inflammation or not. CRI can be due to stimulation of the host
inflammatory response by tumor cells, or tumor cell-derived sol-
uble factors, or to specific activation of inflammatory pathways by
oncogenes. These different pathways result in the production of a
cellular and biochemicalmicroenvironment, the TME, that is con-
ducive to tumor progression and metastatic spreading. However,
how and whether host genes encoding inflammatory mediators
determine tumor progression is an as yet open question. In this
context, identification of the PTX3 gene as a key player in cancer
may also help to better rationalize the role of inflammation in
tumor growth.
We should not be dogmatic in the interpretation of CRI.
Inflammation may not always be “good” for the tumor and
“bad” for the host. We know that tumor-infiltrating immune
cells (e.g., γδ IL-17-producing T cells, CD8+ T lymphocytes,
or type I macrophages) can kill tumor cells (5), and that high
TNFα doses can inhibit tumor growth (6). Coley (7) showed
as early as the late 1890s that bacterial extracts could be used
to treat cancer, and in the same years, similar observations on
the “anti-cancer activity of inflammatory exudates” were also
reported by the Italian Pathologist Eugenio Centanni. Nowa-
days, urologists use bacillus Calmette–Guerin (BCG) for local
treatment of bladder cancer, and with success! It is therefore
clear that CRI can be “good” or “bad” for the host. How can
we turn “bad” CRI into “good” CRI? It is likely that a switch
might be located at the level of host inflammatory cells stimu-
lation by PAMPs and/or damage-associated molecular patterns
(DAMPs). The “Coley” “mélange” of bacterial extracts, like the
BCG suspension used in bladder cancer, promotes a strong
TLR-mediated response that facilitates development of protec-
tive adaptive immunity. This favorable outcome might not only
be due to an efficient PAMP recognition but also to a large
and concomitant release of DAMPs by injured tumor as well
as host cells. It has been proposed that the “way” tumor cells
die, also as a consequence of chemotherapy, is crucial for the
development of an efficient adaptive immune response (immuno-
genic cell death), since factors released from dying cells (e.g.,
ATP, calreticulin, or high-mobility group box 1, HMGB1, pro-
tein) prime tumor-infiltrating dendritic cells for an efficient
Ag presentation to CD8+ T lymphocytes. Stimulation of the
P2X7 receptor, activation of the NLRP3 inflammasome and
enhanced IL-1β release are components of this virtuous path-
way. In addition, it should be noted that some experimental
tumors have a stronger tendency than others to induce the gen-
eration of a “good” inflammatory microenvironment, protective
for the host, probably because they are intrinsically and potently
immunogenic. It is fair to say that molecular mechanisms that
turn “good” into “bad” inflammation are not clear, yet every
effort should be made to get a better insight into this crucial
biological switch point because successful treatment of cancer
patients might in the end reside in our ability to effectively
modify CRI.
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